×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
Vision
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
Vision
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: GHK-Cu — Copper-Binding Tripeptide
therapeutic
993 words
KG: GHK-Cu — Copper-Binding Tripeptide
kind:therapeutic
section:therapeutics
state:published
Contents
GHK-Cu — Copper-Binding Tripeptide
💊
Therapeutic Info
Name
GHK-Cu — Copper-Binding Tripeptide
Summary
GHK-Cu (Glycyl-L-histidyl-L-lysine-Copper) is a copper-binding tripeptide with anti-aging, wound healing, and potential neuroprotective properties.
Knowledge Graph
Related Hypotheses (6)
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Vagal Afferent Microbial Signal Modulation
Score: 0.52
Vocal Cord Neuroplasticity Stimulation
Score: 0.50
Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Score: 0.70
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.38
Show 1 more
Related Analyses (9)
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · completed
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
Show 4 more
Related Experiments (16)
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Show 11 more